Clinical Trial Update: A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom

View source ↗

Summary

A completed UK trial evaluating changes in patient experience for adults with chronic lymphocytic leukemia treated with venetoclax plus rituximab or with Bruton…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• CALQUENCE (ACALABRUTINIB)
• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)
• Venclexta (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia | Status: COMPLETED